How do biomarkers reflect sapropterin's effectiveness?

How do doctors measure sapropterin response in patients?
Blood phenylalanine levels are the primary marker. A drop of at least 20–30 % after one month of treatment signals that the drug is working. Levels are checked weekly at first, then monthly once stable.

What other lab values are tracked alongside phenylalanine?
Doctors also monitor tyrosine, because sapropterin can raise tyrosine while lowering phenylalanine. Liver enzymes and complete blood counts are checked periodically to catch rare side effects early.

Can genetic tests predict who will respond?
Yes. Mutations in the PAH gene that leave some residual enzyme activity often respond to sapropterin. Genotyping is done before starting therapy so clinicians can set realistic expectations and avoid unnecessary long-term use in non-responders.

How quickly do biomarker changes appear?
A measurable fall in phenylalanine can occur within days, but the full therapeutic effect is usually assessed after four weeks. If no meaningful drop is seen by then, treatment is generally discontinued.

What happens if biomarkers do not improve?
The drug is stopped. Patients then return to strict dietary control alone or consider alternative therapies such as pegvaliase. Continuing sapropterin without biomarker improvement adds cost without benefit.

Do biomarkers also guide dose adjustments?
Yes. Once a patient responds, the dose (5–20 mg/kg/day) is titrated to keep phenylalanine in the target range of 120–360 µmol/L. Regular blood tests ensure the dose remains effective as the patient grows or changes diet.

Are there patient-reported signs that align with biomarker data?
Improved mood, concentration, and fewer headaches often coincide with lower phenylalanine, but these subjective reports are never used alone; blood levels remain the deciding factor for continuing or stopping therapy.